Clinical Trial Update: Trial of Ibrutinib Combined With Nivolumab or Cetuximab to Treat Recurrent/Metastatic HNSCC [Phase 2]

View source ↗

Summary

Ongoing Phase 2 clinical trial evaluating the combination of Ibrutinib with Nivolumab or Cetuximab for recurrent/metastatic head and neck cancer; study is curre…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Cancer
• Head and Neck Squamous Cell Carcinoma

Drugs mentioned

• Cetuximab (cetuximab)
• Ibrutinib (ibrutinib)
• nivolumab (nivolumab)

Snippet

Sponsor: University of California, San Diego | Conditions: Head and Neck Cancer, Squamous Cell Carcinoma of the Head and Neck | Phase 2 | Status: ACTIVE_NOT_RECRUITING